Who Generates More Revenue? Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.

Biotech Revenue Race: Regeneron vs. Travere

__timestampRegeneron Pharmaceuticals, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 2014281955700028203205
Thursday, January 1, 2015410372800099892000
Friday, January 1, 20164860427000133591000
Sunday, January 1, 20175872227000154937000
Monday, January 1, 20186710800000164246000
Tuesday, January 1, 20197863400000175338000
Wednesday, January 1, 20208497100000198321000
Friday, January 1, 202116071700000227490000
Saturday, January 1, 202212172900000212018000
Sunday, January 1, 202313117200000145238000
Monday, January 1, 202414202000000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the competitive world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Regeneron Pharmaceuticals, Inc. has consistently outperformed Travere Therapeutics, Inc. in terms of revenue generation. From 2014 to 2023, Regeneron's revenue surged by approximately 365%, peaking in 2021 with a remarkable 470% increase compared to its 2014 figures. In contrast, Travere Therapeutics experienced a more modest growth of around 415% during the same period, with its highest revenue recorded in 2021.

Regeneron's strategic focus on innovative therapies has propelled its financial success, while Travere's niche approach in rare diseases has shown steady, albeit slower, growth. This data highlights the diverse strategies within the biotech sector and underscores the importance of innovation and market positioning in driving revenue growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025